175 related articles for article (PubMed ID: 60819)
1. Inhibition by estramustine phosphate on estradiol and androgen binding in benign and malignant prostate in humans.
Nilsson I; Liskowski L; Nilsson T
Urology; 1976 Aug; 8(2):118-21. PubMed ID: 60819
[TBL] [Abstract][Full Text] [Related]
2. Estramustine phosphate: metabolic aspects related to its action in prostatic cancer.
Kadohama N; Kirdani RY; Murphy GP; Sandberg AA
J Urol; 1978 Feb; 119(2):234-9. PubMed ID: 633484
[TBL] [Abstract][Full Text] [Related]
3. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacology and metabolism of a new therapeutic drug for prostatic cancer "Estracyt"].
Yamanaka H; Shida K
Gan To Kagaku Ryoho; 1984 Mar; 11(3):537-44. PubMed ID: 6422861
[TBL] [Abstract][Full Text] [Related]
5. Interaction of the cytotoxic agent estramustine phosphate (Estracyt) with the estrogen receptor of the human uterus.
Muechler EK; Kohler D
Gynecol Oncol; 1979 Dec; 8(3):330-8. PubMed ID: 510999
[No Abstract] [Full Text] [Related]
6. Metabolism of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
Andersson SB; Gunnarsson PO; Nilsson T; Forshell GP
Eur J Drug Metab Pharmacokinet; 1981; 6(2):149-54. PubMed ID: 7274309
[TBL] [Abstract][Full Text] [Related]
7. Effect of a steroidal alkylating agent (estramustine phosphate) in rat ventral prostate.
Høisaeter PA
Scand J Urol Nephrol Suppl; 1977; (46):1-72. PubMed ID: 279091
[No Abstract] [Full Text] [Related]
8. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Pharmacol; 1998 May; 55(9):1427-33. PubMed ID: 10076535
[TBL] [Abstract][Full Text] [Related]
9. [Estracyt (estradiol-nitrogen mustard complex)--estramustine binding protein and its specificity].
Yamanaka H; Imai K; Suzuki T; Yuasa H; Takahashi E
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2106-14. PubMed ID: 6486830
[TBL] [Abstract][Full Text] [Related]
10. Mode of action of Emcyt.
Høisaeter PA
Urology; 1984 Jun; 23(6 Suppl):46-8. PubMed ID: 6375079
[No Abstract] [Full Text] [Related]
11. The synthesis of 3H labelled steroid-nitrogen mustard derivatives and studies on their action in rat and human prostate.
Symes EK; Milroy EJ
J Steroid Biochem; 1982 Jul; 17(1):23-30. PubMed ID: 7109589
[TBL] [Abstract][Full Text] [Related]
12. Intracellular effects of estramustine (Estracyt/Emcyt).
Tew KD; Stearns ME
Prog Clin Biol Res; 1989; 303():169-75. PubMed ID: 2674983
[No Abstract] [Full Text] [Related]
13. Treatment of oral estramustine phosphate (Estracyt) in prostatic carcinoma: influences on lipid and carbohydrate metabolism.
Gustafson A; Persson B; Tisell LE; Wiklund O; Ohlson R
Invest Urol; 1977 Nov; 15(3):220-4. PubMed ID: 591268
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt).
Gunnarsson PO; Forshell GP; Fritjofsson A; Norlén BJ
Scand J Urol Nephrol; 1981; 15(3):201-5. PubMed ID: 7323739
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of 3H-thymidine and 14C-amino acids into the ventral prostate after in vivo treatment with estradiol-3N-BIS(2-chloroethyl)carbamate-17 beta-phosphate (Estracyt) and its estrogen and cytostatic parts.
Hoisaeter PA
Invest Urol; 1976 Sep; 14(2):85-92. PubMed ID: 972011
[TBL] [Abstract][Full Text] [Related]
16. [Clinical studies on serum lipids in the patients with tumor of the prostate gland. 2nd. Report. Changes of serum lipids and lipoprotein fractions during the treatment of estramustine phosphate disodium, hexestrol and diethylstilbestrol 4, 4-diphosphoric ester for the patients with prostatic cancer (author's transl)].
Yoshida H; Shimada M
Nihon Hinyokika Gakkai Zasshi; 1980 Jan; 71(1):59-69. PubMed ID: 6155501
[TBL] [Abstract][Full Text] [Related]
17. Binding sites for the cytotoxic metabolites of estramustine phosphate (Estracyt) in rat and human pancreas that are distinct from pancreatic estrogen-binding protein.
Björk P; Jönsson U; Andrén-Sandberg A
Pancreas; 1991 Jan; 6(1):77-89. PubMed ID: 1994382
[TBL] [Abstract][Full Text] [Related]
18. Androgens and estrogens in the plasma and prostatic tissue of normal dogs and dogs with benign prostatic hypertrophy.
Lloyd JW; Thomas JA; Mawhinney MG
Invest Urol; 1975 Nov; 13(3):220-22. PubMed ID: 53217
[TBL] [Abstract][Full Text] [Related]
19. Estramustine phosphate (Estracyt): experimental and clinical studies in Europe.
Hoisaeter PA; Bakke A
Semin Oncol; 1983 Sep; 10(3 Suppl 3):27-33. PubMed ID: 6364363
[No Abstract] [Full Text] [Related]
20. Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145).
Hartley-Asp B; Gunnarsson PO
J Urol; 1982 Apr; 127(4):818-22. PubMed ID: 7069864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
